Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Shire To Pay $75 Million For Fibrosis Specialist

by Rick Mullin
May 12, 2014 | A version of this story appeared in Volume 92, Issue 19

Irish drug company Shire will acquire Fibrotech, an Australian biopharmaceutical company, for $75 million. Fibrotech is developing a new class of drugs to treat health effects associated with fibrosis. The hook for Shire is Fibrotech’s lead product FT011, a therapy targeting focal segmental glomerulosclerosis (FSGS), currently in Phase I clinical trials. FSGS is a rare disease that affects the kidney’s filtering system and causes serious scarring.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.